Centessa Pharmaceuticals (CNTA)
NASDAQ:CNTA
Top Page
Centessa Pharmaceuticals
(NASDAQ:CNTA)
Select Model
Select Model
Rating:66Neutral
Price Target:
$43.00
▲(8.67% Upside)
Action:ReiteratedDate:04/01/26
The score is driven by the announced Lilly acquisition (supportive near-term value anchor) and strong technical momentum, partially offset by weak operating performance with ongoing losses and cash burn, and limited traditional valuation support due to negative earnings.
Positive Factors
Low leverage / strong balance sheet
Centessa's very low debt versus a sizable equity and asset base gives the company durable financial flexibility to fund clinical programs, pursue strategic options, and withstand development risk without heavy interest burdens. This preserves optionality over multiple quarters.
Negative Factors
Sustained cash burn
Large, persistent negative operating and free cash flow indicates the company requires external capital or a transaction to fund ongoing R&D. Over a multi-quarter horizon, continued cash burn is a structural constraint that limits independent advancement of programs absent new funding or a deal close.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Centessa's very low debt versus a sizable equity and asset base gives the company durable financial flexibility to fund clinical programs, pursue strategic options, and withstand development risk without heavy interest burdens. This preserves optionality over multiple quarters.
Read all positive factors
Centessa Pharmaceuticals (CNTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.89B
Dividend YieldN/A
Average Volume (3M)3.53M
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue Growth117.83%
EPS Growth-18.91%
CountryUS
Employees77
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.40
Shares Outstanding154,568,530
10 Day Avg. Volume7,655,810
30 Day Avg. Volume3,529,951
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)6.44
Price to Sales (P/S)226.28
P/FCF Ratio-17.48
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue390.08
Enterprise Value/Gross Profit396.12
Enterprise Value/Ebitda-28.17
Forecast
1Y Price Target
$45.00Price Target Upside13.72% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)-1.69
Revenue Forecast (FY)N/A
Centessa Pharmaceuticals Business Overview & Revenue Model
Company Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in ...
How the Company Makes Money
null...
Centessa Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 15.00M | 0.00 | 6.85M | 0.00 | 0.00 |
| Gross Profit | 15.00M | 0.00 | 6.85M | 0.00 | 0.00 |
| EBITDA | -207.69M | -221.88M | -165.43M | -209.55M | -139.30M |
| Net Income | -197.53M | -235.76M | -151.09M | -216.21M | -381.90M |
Balance Sheet | |||||
| Total Assets | 687.50M | 576.80M | 360.25M | 444.31M | 629.63M |
| Cash, Cash Equivalents and Short-Term Investments | 294.58M | 482.18M | 256.55M | 393.64M | 595.08M |
| Total Debt | 7.57M | 117.23M | 84.59M | 69.80M | 75.70M |
| Total Liabilities | 160.63M | 175.25M | 124.00M | 108.14M | 138.08M |
| Stockholders Equity | 526.86M | 401.55M | 236.24M | 336.17M | 491.55M |
Cash Flow | |||||
| Free Cash Flow | -194.19M | -142.09M | -160.51M | -201.68M | -136.33M |
| Operating Cash Flow | -193.82M | -142.06M | -160.34M | -200.55M | -136.14M |
| Investing Cash Flow | -418.53M | 31.27M | -127.00M | -931.00K | 63.25M |
| Financing Cash Flow | 291.53M | 364.75M | 21.12M | 457.00K | 660.07M |
Centessa Pharmaceuticals Technical Analysis
Positive
39.57
Price Trends
28.35
Positive
27.11
Positive
23.25
Positive
Market Momentum
3.62
Negative
75.57
Negative
94.82
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTA, the sentiment is Positive. The current price of 39.57 is above the 20-day moving average (MA) of 32.63, above the 50-day MA of 28.35, and above the 200-day MA of 23.25, indicating a bullish trend. The MACD of 3.62 indicates Negative momentum. The RSI at 75.57 is Negative, neither overbought nor oversold. The STOCH value of 94.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CNTA.
Centessa Pharmaceuticals Risk Analysis
Centessa Pharmaceuticals disclosed 109 risk factors in its most recent earnings report. Centessa Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Centessa Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $5.89B | -17.18 | -50.66% | ― | 117.83% | -18.91% | |
62 Neutral | $4.99B | -10.43 | -65.80% | ― | ― | -27.70% | |
58 Neutral | $5.57B | -10.27 | -55.81% | ― | ― | -38.30% | |
56 Neutral | $5.21B | -13.43 | 8.20% | ― | 42.11% | ― | |
56 Neutral | $5.74B | -13.37 | -145.91% | ― | ― | -31.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $2.25B | -3.94 | -1024.42% | ― | 20.63% | 8.09% |
* Healthcare Sector Average
CNTA
Centessa Pharmaceuticals
39.57
27.63
231.41%
RARE
Ultragenyx Pharmaceutical
23.63
-11.29
-32.33%
XENE
Xenon
58.60
25.16
75.24%
APLS
Apellis Pharmaceuticals
40.84
21.51
111.28%
SRRK
Scholar Rock Holding
49.52
20.59
71.17%
IMVT
Immunovant
25.12
9.69
62.80%
Centessa Pharmaceuticals Corporate Events
Business Operations and StrategyM&A Transactions
Eli Lilly to Acquire Centessa Pharmaceuticals in Cash Deal
Positive
Apr 1, 2026
On March 31, 2026, Eli Lilly and Company agreed to acquire Centessa Pharmaceuticals via a court-sanctioned scheme of arrangement in the U.K., paying $38 in cash per share plus a non-transferable contingent value right (CVR) worth up to an addition...
Executive/Board Changes
Centessa Pharmaceuticals CEO Transition to Advisory Role Finalized
Neutral
Feb 13, 2026
Centessa Pharmaceuticals announced leadership changes that took effect on January 1, 2026, when Saurabh Saha, M.D., Ph.D., stepped down as Chief Executive Officer and as a member of the Board of Directors. On February 9, 2026, the company formaliz...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.